Sitemap
- Home
- Dermatology
- Respiratory
- Cardiology
- Dyslipidaemia
- Articles
- Praluent® (alirocumab) mechanism of action
- Cardiovascular outcomes for diabetes patients Praluent® (alirocumab)
- ODYSSEY OUTCOMES Efficacy Praluent® (alirocumab)
- ESC/EAS DYSLIPIDAEMIA GUIDELINE INTERACTIVE (1 HOUR)
- ESC/EAS DYSLIPIDAEMIA GUIDELINE INTERACTIVE (2 MINUTES)
- FH I & FH II Studies Praluent® (alirocumab)
- ESC/EAS DYSLIPIDAEMIA GUIDELINE INTERACTIVE (20 MINUTES)
- A cardiologist's view - Professor Azfar Zaman
- ODYSSEY OUTCOMES Safety Profile Praluent® (alirocumab)
- Therapeutic indications for Praluent® (alirocumab)
- NICE and SMC Guidance Praluent® (alirocumab)
- Dosing options – customise your patient’s treatment with Praluent® (alirocumab)
- Praluent® (alirocumab) PubExplainer
- ODYSSEY OUTCOMES Trial Design Praluent® (alirocumab)
- Praluent® (alirocumab) Administration
- Specific characteristics of Praluent® (alirocumab)
- Unmet Needs in Dyslipidaemia
- Resources
- Education
- HEART UK
- Implementing Artificial Intelligence to Risk Stratify, Manage and Refer Patients
- The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS
- Strengthening the Interface Between Primary and Secondary Care
- New Approaches and Innovation in Lipid Services – Strengthening the Relationship between Primary and Secondary Care
- What's the Future of Secondary Care Lipid Services?
- Articles
- Thrombosis
- Dyslipidaemia
- Other Topics
- Rare Disease
- Oncology
- Multiple Myeloma
- Articles
- About Multiple Myeloma
- A Real World Case Study : Presented by Dr Kenny Douglas
- A Real World Case Study : Presented by Dr Ceri Bygrave
- A Real World Case Study: Presented by Dr Sarah Lawless
- A Real World Case Study : Presented by Dr Karthik Ramasamy
- A Real World Case Study : Presented by Dr Jane Clark
- Independent UK Real World Data. Data from 107 patients from 24 centres across the UK.
- Overview of the safety and efficacy data from ICARIA-MM Trial
- A Real World Case Study: Presented by Christine Skeet
- Resources
- Articles
- Other Oncology Topics
- Multiple Myeloma
- Vaccines
- Diabetes
- Type 1 Diabetes
- Articles
- T1 Evidence in Children
- T1 Evidence in Adults
- Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T1DM
- T1DM - Meta-Analysis
- Toujeo (insulin glargine 300 Units/mL) Versus insulin glargine 100 units/mL in T1DM
- T1 Edition Junior Study
- Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T1DM
- InRange Study
- SPARTA study
- Resources
- Education
- Articles
- Type 2 Diabetes
- Articles
- Video: BRIGHT study
- ORION Observational Study
- Hospitalisation rates with basal insulin in adults with T2D
- Benefits of switching to Toujeo (insulin glargine 300 Units/mL) through patient case studies and patient reported outcomes
- Explore Toujeo (insulin glargine 300 Units/mL) data from the pivotal randomised controlled clinical trials
- Patient satisfaction with Toujeo (insulin glargine 300 Units/mL) in adults with T2D
- Toujeo (insulin glargine 300 Units/mL) in addition to GLP1-RA
- Treatment persistence with basal insulin in adults with T2D
- Toujeo (insulin glargine 300 Units/mL) Versus insulin glargine 100 units/mL in T2DM
- Head to Head Studies
- Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T2DM
- Head to Head Studies
- Events
- Education
- Diabetes UK 2024: Connecting the Dots: Benefits of pen connectivity for people living with diabetes
- Paradigm 2024: Ketan Dhatariya
- Diabetes UK 2023: Cultural humility in diabetes consultation
- Paradigm 2024: Lesley Mills
- Diabetes UK 2024: Navigating Hyperglycaemia after GLP-1s with Insulin
- Diabetes Podcast Series | Toujeo® (insulin glargine 300 Units/mL) | Lantus® (insulin glargine 100 units/mL)
- What Insulins Do I Need In My Toolbox To Support People With Type 2 Diabetes
- Practicalities of Supporting the Teenager With Type 2 Diabetes
- Diabetes UK 2024: Sustainably scripting tomorrow with Sanofi's Planet Cares Programme and Pen Recycling pilot
- Paradigm 2024: Saqib Mahmud
- Articles
- Type 1 Diabetes
- Transplant
- Transplant
- Articles
- Education
- EBMT 2024: The late effects of chronic GvHD: The challenge of long-term management
- EBMT 2024: QoL and chronic GvHD
- EBMT 2024: Treatment of steroid refractory chronic GvHD
- InTen Nurse Forum - ACCEND Framework
- EBMT 2024: Frontline treatment of chronic GvHD
- InTen Nurse Forum: What is chronic GvHD?
- EBMT 2024: Roundtable: Exploring clinical cases
- EBMT 2024: Expanding the cGvHD treatment paradigm with novel therapeutics
- EBMT 2024: Advances in the biology of chronic GvHD
- EBMT 2024: Pulmonary chronic GvHD: The need for early identification and improved management
- EBMT 2024: Expert Exchange: Exploring the clinical practicalities of managing GvHD
- Transplant
- Neurology
- Products
- Supemtek▼
- Cerdelga®▼(Eliglustat)
- Quadrivalent Influenza Vaccine
- Lemtrada®
- Praluent®
- Vaxelis®
- Cerezyme®
- Myozyme®
- SARCLISA®▼
- Rezurock®▼
- Lantus®
- Admelog®
- Quadrivalent Influenza Vaccine▼
- Toujeo®
- Trurapi®▼
- Fabrazyme®
- MenQuadfiTM▼
- Dupixent® (dupilumab) Atopic Dermatitis
- DUPIXENT® (dupilumab) Severe Asthma
- Viatim®
- Clexane®
- Nexviadyme® ▼
- Aldurazyme®
- Dupixent® (dupilumab) Prurigo Nodularis
- Therapeutic Areas
- Sitemap
- Sign Up
- Sign In
- Terms of Use
- Privacy Policy
- Cookie Policy